AKTS
Aktis Oncology·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
EPS Beats Expectation
Bearish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AKTS
Aktis Oncology, Inc.
A clinical-stage oncology company
17 Drydock Avenue
Suite 17-401
Boston
Massachusetts 02210
--
Aktis Oncology, Inc. was incorporated under the laws of the State of Delaware in August 2020. The company is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to a large patient population, including those unresolved by existing platform technologies. The company's vision is to redefine cancer therapy, and the company is advancing a proprietary micro-protein radioactive coupling platform designed to deliver radioisotopes directly to tumors, enhancing therapeutic effects while minimizing systemic radiation exposure. Aktis Oncology's pilot program is targeting Nectin-4 and is currently in clinical development for locally advanced or metastatic urothelial carcinoma and other solid tumors. The company has leveraged its expertise in radiopharmaceutical development and supply chain management to create a portfolio of innovative therapeutic drug candidates designed to address multiple tumor types that are not adequately targeted by current therapies.
Company Financials
Revenue & Expenses
AKTS has released its 2024 Q4 earnings report, with revenue of 933.00K, reflecting a YoY change of NaN%, and net profit of -12.06M, showing a YoY change of -43.29%. The Sankey diagram below clearly presents AKTS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
